Following disease progression, molecular markers (e.g., BAP1 status) should be evaluated, and consideration should be given to anti-angiogenic agents (e.g., bevacizumab) or targeted therapies (per the 2025 Clinical Practice Guidelines for Histopathological Diagnosis of Mesothelioma). This evidence concerns the gene BAP1 and mesothelioma.